风湿性二尖瓣病变60岁以上患者:二尖瓣修复与生物瓣置换的倾向性评分匹配结果
该回顾性研究纳入2011至2023年安贞医院981例60岁以上风湿性二尖瓣病变患者,经倾向性评分匹配后各254例比较二尖瓣修复与生物瓣置换。结论认为修复可作为60岁以上风湿性二尖瓣病变患者可选的外科干预方式。
要点
- 60岁以上风湿性二尖瓣病变患者中,修复与生物瓣置换的晚期死亡率相当。
- 修复组围术期手术时间更短、输血需求更少、围术期再手术率更低。
- 除重度二尖瓣反流外,两组瓣膜相关再手术率与不良事件相似。
核心结论
- 60岁以上风湿性二尖瓣病变患者中,二尖瓣修复与生物瓣置换的中长期生存和围术期死亡率相当。
- 二尖瓣修复被视为60岁以上风湿性二尖瓣病变患者可选的外科干预方式。
研究设计与样本
- 回顾性分析2011年1月至2023年6月安贞医院60岁及以上接受二尖瓣修复或生物瓣置换的风湿性二尖瓣病变患者。
- 共纳入981例,修复组317例、生物瓣置换组664例;倾向性评分匹配后每组254例。
- 采用Kaplan-Meier生存分析评估中长期生存与再手术率,计算晚期死亡风险比及以死亡为竞争风险的再手术亚分布风险比。
主要发现
- 匹配后患者中位年龄64岁(四分位距6年),中位随访4.8年。
- 修复组手术时间显著更短、输血需求更少、围术期再手术率更低。
- 除重度二尖瓣反流外,两组瓣膜相关再手术率与不良事件相似。
临床怎么用
- 对60岁以上风湿性二尖瓣病变患者,二尖瓣修复可作为可选术式,其晚期生存与生物瓣置换相当。
- 修复组围术期恢复指标更优,可作为制定个体化手术策略的参考。
局限性
- 本研究为单中心回顾性分析,结论可能受选择偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatic mitral valve disease remains a significant health issue in developing countries, especially among elderly patients with severe valvular abnormalities. The optimal surgical intervention-mitral valve repair versus bioprosthetic mitral valve replacement-for patients aged more than 60 years is debated because of limited studies in this age group. We aimed to compare mid- to long-term outcomes of mitral valve repair and bioprosthetic mitral valve replacement in elderly patients with rheumatic mitral valve disease. METHODS: We retrospectively analyzed patients aged 60 years or more who underwent mitral valve repair or bioprosthetic mitral valve replacement at Anzhen Hospital from January 2011 to June 2023. Propensity score matching was used to balance the groups. Kaplan-Meier survival analysis assessed mid- to long-term survival and reoperation rates. Subsequently, the hazard ratio for late mortality and the subdistribution hazard ratio for reoperation, considering death as a competing risk, were calculated. RESULTS: The study included 981 patients, with 317 in the mitral valve repair group and 664 in the bioprosthetic mitral valve replacement group. After propensity score matching, 254 patients from each group were included. After propensity score matching, patients had a median age of 64 years (interquartile range, 6 years). The mitral valve repair group had significantly shorter operative times, less need for blood transfusions, and lower perioperative reoperation rates. At a median follow-up of 4.8 years, patients undergoing mitral valve repair had comparable late mortality compared with bioprosthetic mitral valve replacement (hazard ratio, 0.637; 95% CI, 0.355-1.143; P = .130). Valve-related reoperation rates and adverse events, except for severe mitral regurgitation, were similar between groups. CONCLUSIONS: Among patients aged more than 60 years with rheumatic mitral valve disease, valve repair is associated with comparable mid- to long-term survival and perioperative mortality when compared with bioprosthetic valve replacement. Mitral valve repair is regarded as an optional surgical intervention for patients aged more than 60 years who have experienced rheumatic mitral valve disease.
引用
- Zhang W, Luo T, Meng F, et al. Mitral valve repair versus bioprosthetic replacement outcomes in patients with rheumatic disease over 60: Propensity score-matching results. J Thorac Cardiovasc Surg. 2025. PMID: 40187555. doi:10.1016/j.jtcvs.2025.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。